Amphastar Pharmaceuticals
AMPH
92 hedge funds and large institutions have $160M invested in Amphastar Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 12 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 23
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
8% more funds holding
Funds holding: 85 → 92 (+7)
31% less capital invested
Capital invested by funds: $234M → $160M (-$73.4M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.38M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
+$3.48M |
| 3 |
SAMC
Shinko Asset Management Company
Tokyo,
Japan
|
+$3.48M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.25M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.88M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$3.63M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.04M |
| 4 |
Renaissance Technologies
New York
|
-$2.79M |
| 5 |
Two Sigma Investments
New York
|
-$2.65M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
101
Tower Research Capital (TRC)
New York
| – | -$52K | -2,960 | Closed |
|
|
QT
102
Quantbot Technologies
New York
| – | -$22K | -1,300 | Closed |
|
|
CCS
103
Crosspoint Capital Strategies
Orinda,
California
| – | -$10K | -596 | Closed |
|
104
Invesco
Atlanta,
Georgia
| – | -$5K | -307 | Closed |
|
AMPH Hedge Fund Activity: Q3 2015 in Review
92 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2015, worth a combined $160M — down 31% from $234M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AMPH positions and 12 closed out — a net gain of 7 holders — while 37 added to existing stakes and 23 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $4.38M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.88M sold.
- 92 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2015, up from 85 in Q2 2015.
- Funds reported $160M of Amphastar Pharmaceuticals stock for Q3 2015, down 31% quarter-over-quarter.
- 19 funds opened new Amphastar Pharmaceuticals positions in Q3 2015 and 12 closed out, a net change of +7 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2015 was Fidelity Investments, an estimated $4.38M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2015 was Deerfield Management, an estimated $7.88M sold.
Based on aggregated 13F filings for Q3 2015.